Expert perspectives real-world clinical experiences in relapsed myeloma
|
|
- Annabella Jordan
- 6 years ago
- Views:
Transcription
1 Takeda Oncology-sponsored satellite symposium at the British Society for Haematology (BSH) 57 th Annual Scientific Meeting Expert perspectives real-world clinical experiences in relapsed myeloma This satellite symposium was organised and fully funded by Takeda UK Ltd. Takeda medicines were discussed during this meeting. Prescribing information is available on the final slide. The views expressed during this presentation are those of the speaker. Zinc code: UK/IXA/1612/0107e. Date of preparation: May 2017.
2 Statement on NINLARO (ixazomib) availability NINLARO has received approval for the following indication: NINLARO in combination with lenalidomide and dexamethasone is indicated for the of adult patients with multiple myeloma who have received at least one prior therapy NINLARO is currently not commercially available NINLARO is awaiting relevant Health Technology Appraisals (HTAs) and commercial stock will become available upon confirmed availability of NHS funding
3 Objectives To provide insights on the real-world use of ixazomib using experiences from the UK and the US, citing clinician and patient experiences and perspectives from the introduction of ixazomib To facilitate discussions surrounding the practicalities and learnings from ixazomib use in clinical practice, drawing on these experiences utilising short case studies To explore how the introduction of ixazomib will impact on the paradigm in the UK
4 Disclosures Dr Popat has received advisory board and speaker fees from: Janssen Novartis Takeda Dr Jenner has received advisory board and speaker fees from: Amgen Novartis Celgene Takeda Janssen Dr Ramasamy has received advisory board and speaker fees from: Amgen Janssen Celgene Takeda
5 Case study 1: (Dr Rakesh Popat) Age Occupation 58 years Dentist Presentation Presentation with back pain. Diagnosis: IgA lambda myeloma; ISS 3; BM: 70% plasma cells; FISH: 1q+ (95% cells), del 13 (81%) Fracture T6, large T12 lesion, multiple other foci ASCT, autologous stem cell transplant; BM, bone marrow; CR, complete response; FDG, fluorodeoxyglucose; FISH, fluorescence in situ hybridisation; Ig, immunoglobulin; ISS, International Staging System; PET-CT, positron emission tomography - computed tomography; QoL, quality of life; Rd, lenalidomide-dexamethasone; VGPR, very good partial response; VTD, bortezomib-thalidomide-dexamethasone.
6 Case study 1: (Dr Rakesh Popat) Age Occupation 58 years Dentist Presentation Presentation with back pain. Diagnosis: IgA lambda myeloma; ISS 3; BM: 70% plasma cells; FISH: 1q+ (95% cells), del 13 (81%) Fracture T6, large T12 lesion, multiple other foci Initial VTD x 5; VGPR; ASCT: response CR; no maintenance Decision point 15 months later: Reappearance of bands <3; 18 months later: IgA 25, new rib & back pain ASCT, autologous stem cell transplant; BM, bone marrow; CR, complete response; FDG, fluorodeoxyglucose; FISH, fluorescence in situ hybridisation; Ig, immunoglobulin; ISS, International Staging System; PET-CT, positron emission tomography - computed tomography; QoL, quality of life; Rd, lenalidomide-dexamethasone; VGPR, very good partial response; VTD, bortezomib-thalidomide-dexamethasone.
7 Case study 1: (Dr Rakesh Popat) Age Occupation 58 years Dentist Presentation Presentation with back pain. Diagnosis: IgA lambda myeloma; ISS 3; BM: 70% plasma cells; FISH: 1q+ (95% cells), del 13 (81%) Fracture T6, large T12 lesion, multiple other foci Initial VTD x 5; VGPR; ASCT: response CR; no maintenance Decision point 15 months later: Reappearance of bands <3; 18 months later: IgA 25, new rib & back pain Second Decision point Pulsed dexamethasone. Restaged: BM 70% plasma cells; cytogenetics: Hyperdiploid, 1q+, IgH rearrangement unknown partner; PET-CT: Multiple FDG avid foci Treatment options discussed: 2nd ASCT; clinical trial/bortezomib combination; Rd combinations: daratumumab-rd; carfilzomib-rd; ixazomib-rd ASCT, autologous stem cell transplant; BM, bone marrow; CR, complete response; FDG, fluorodeoxyglucose; FISH, fluorescence in situ hybridisation; Ig, immunoglobulin; ISS, International Staging System; PET-CT, positron emission tomography - computed tomography; QoL, quality of life; Rd, lenalidomide-dexamethasone; VGPR, very good partial response; VTD, bortezomib-thalidomide-dexamethasone.
8 Case study 1: (Dr Rakesh Popat) Age Occupation 58 years Dentist Presentation Presentation with back pain. Diagnosis: IgA lambda myeloma; ISS 3; BM: 70% plasma cells; FISH: 1q+ (95% cells), del 13 (81%) Fracture T6, large T12 lesion, multiple other foci Initial VTD x 5; VGPR; ASCT: response CR; no maintenance Decision point 15 months later: Reappearance of bands <3; 18 months later: IgA 25, new rib & back pain Second Decision point Third Pulsed dexamethasone. Restaged: BM 70% plasma cells; cytogenetics: Hyperdiploid, 1q+, IgH rearrangement unknown partner; PET-CT: Multiple FDG avid foci Treatment options discussed: 2nd ASCT; clinical trial/bortezomib combination; Rd combinations: daratumumab-rd; carfilzomib-rd; ixazomib-rd Ixazomib-Rd cycle 1: IgA 30; currently cycle 6: IgA 9.45 ASCT, autologous stem cell transplant; BM, bone marrow; CR, complete response; FDG, fluorodeoxyglucose; FISH, fluorescence in situ hybridisation; Ig, immunoglobulin; ISS, International Staging System; PET-CT, positron emission tomography - computed tomography; QoL, quality of life; Rd, lenalidomide-dexamethasone; VGPR, very good partial response; VTD, bortezomib-thalidomide-dexamethasone.
9 Case study 1: (Dr Rakesh Popat) Age Occupation 58 years Dentist Presentation Presentation with back pain. Diagnosis: IgA lambda myeloma; ISS 3; BM: 70% plasma cells; FISH: 1q+ (95% cells), del 13 (81%) Fracture T6, large T12 lesion, multiple other foci Initial VTD x 5; VGPR; ASCT: response CR; no maintenance Decision point 15 months later: Reappearance of bands <3; 18 months later: IgA 25, new rib & back pain Second Decision point Third Pulsed dexamethasone. Restaged: BM 70% plasma cells; cytogenetics: Hyperdiploid, 1q+, IgH rearrangement unknown partner; PET-CT: Multiple FDG avid foci Treatment options discussed: 2nd ASCT; clinical trial/bortezomib combination; Rd combinations: daratumumab-rd; carfilzomib-rd; ixazomib-rd Ixazomib-Rd cycle 1: IgA 30; currently cycle 6: IgA 9.45 Learnings Continues to work full time; minimal disruption and good QoL ASCT, autologous stem cell transplant; BM, bone marrow; CR, complete response; FDG, fluorodeoxyglucose; FISH, fluorescence in situ hybridisation; Ig, immunoglobulin; ISS, International Staging System; PET-CT, positron emission tomography - computed tomography; QoL, quality of life; Rd, lenalidomide-dexamethasone; VGPR, very good partial response; VTD, bortezomib-thalidomide-dexamethasone.
10 First interim analysis: median follow-up of ~15 months Ixazomib-Rd extends PFS across a broad group of patients vs. placebo-rd n Median PFS (months) Variable Subgroup Ixazomib-Rd Placebo-Rd Ixazomib-Rd Placebo-Rd HR All patients ALL Age (years) ISS stage Cytogenetic risk 65 >65-75 >75 I or II III Standard-risk High-risk Number of prior therapies 1 2 or NE Proteasome inhibitor Exposed Naive NE Prior IMiD therapy Exposed Naive NE Relapsed or refractory Relapsed Refractory* Relapsed & Refractory NE NE Baseline CrCl group <50 ml/min 50 ml/min TOURMALINE-MM1 was not powered to assess efficacy in any specific subgroups, and as multiple myeloma is a heterogeneous disease, benefit may vary across subgroups Favours ixazomib-rd Favours placebo-rd Figure adapted from NINLARO Summary of Product Characteristics NINLARO (ixazomib capsules) Summary of Product Characteristics March *Includes primary refractory patients. CrCL, creatinine clearance; HR, hazard ratio; IMiD, immunomodulatory drug; ISS, International Staging System; NE, not estimable; PFS, progression-free survival; Rd, lenalidomide-dexamethasone.
11 Peripheral neuropathy Peripheral neuropathy (PN) in TOURMALINE-MM1 1 Grade 3 PN was reported in 2% of patients in both groups in TOURMALINE-MM1 No grade 4 PN events were reported in either group Management of PN 2 Patients on ixazomib should be monitored for symptoms of neuropathy For grade 1 PN with pain or grade 2 PN, withhold ixazomib until PN recovers to grade 1 without pain or patient s baseline and then resume ixazomib at its most recent dose For grade 2 PN with pain or grade 3 PN, withhold ixazomib. Toxicities should, at the physician s discretion, generally recover to patient s baseline condition or grade 1 prior to resuming ixazomib at the next lower dose Discontinue regimen for grade 4 PN 1. Moreau P et al. N Engl J Med 2016;374: ; 2. NINLARO (ixazomib capsules) Summary of Product Characteristics March PN, peripheral neuropathy.
12 No difference in response by prior PI exposure 1,2 In TOURMALINE-MM1, 70% of patients had prior PI exposure (69% to bortezomib; 1% to carfilzomib) No difference was seen in response stratified by prior PI exposure Median PFS (months) Variable Subgroup Ixazomib-Rd Placebo-Rd HR All patients ALL Proteasome inhibitor Exposed Naive 18.4 NE Favours ixazomib-rd Favours placebo-rd Figure adapted from NINLARO Summary of Product Characteristics 1. Moreau P et al. N Engl J Med 2016;374: ; 2. NINLARO (ixazomib capsules) Summary of Product Characteristics March HR, hazard ratio; NE, not estimable; PI, proteasome inhibitor; PFS, progression-free survival; Rd, lenalidomide-dexamethasone.
13 Case study 2 (Dr Matthew Jenner) Age 58 years Diagnosis February 2010 Presentation Physical condition: Fatigue; back pain; Investigations: IgG lambda paraprotein 31 g/l; Hb 125 g/l; renal function and calcium normal; ISS 2; skeletal survey vertebral collapse T11; BMA: 70% plasma cells; no FISH available Initial CTD x6; paraprotein pre-asct 12g/L (PR); High dose melphalan (200 mg/m 2 ) ASCT December 2010; nadir paraprotein 3 g/l (VGPR) ASCT, autologous stem cell transplant; BMA, bone marrow aspirate; CTD, cyclophosphamide-thalidomide-dexamethasone; FISH, fluorescence in situ hybridisation; Hb, haemoglobin; Ig, immunoglobulin; ISS, International Staging System; PR, partial response; VGPR, very good partial response.
14 Case study 2 (Dr Matthew Jenner) Age 58 years Diagnosis February 2010 Presentation Physical condition: Fatigue; back pain; Investigations: IgG lambda paraprotein 31 g/l; Hb 125 g/l; renal function and calcium normal; ISS 2; skeletal survey vertebral collapse T11; BMA: 70% plasma cells; no FISH available Second Serological progression October 2011: Paraprotein 14 g/l; Clinical progression January 2012: Paraprotein 21 g/l; Hb 120 g/l; BMA 46% plasma cells; FISH: t(4;14) in 100%; del (17p) in 30%; Chromosome 1 failed; Myeloma X trial: PAD x4, paraprotein fell to 4.3 g/l; 2nd high dose melphalan (200 mg/m 2 ) ASCT; post ASCT nadir 1.4 g/l; Serological progression 10 months post 2nd ASCT ASCT, autologous stem cell transplant; BMA, bone marrow aspirate; CTD, cyclophosphamide-thalidomide-dexamethasone; FISH, fluorescence in situ hybridisation; Hb, haemoglobin; Ig, immunoglobulin; ISS, International Staging System; PAD, bortezomib-doxorubicin-dexamethasone; PR, partial response; VGPR, very good partial response.
15 Case study 2 (Dr Matthew Jenner) Age 58 years Diagnosis February 2010 Presentation Physical condition: Fatigue; back pain; Investigations: IgG lambda paraprotein 31 g/l; Hb 125 g/l; renal function and calcium normal; ISS 2; skeletal survey vertebral collapse T11; BMA: 70% plasma cells; no FISH available DOR: 24 months DOR: 18 months DOR: 26 months Third September 2013: Paraprotein peak 29 g/l, total IgG 71.6 g/l; Hb 113; BMA: heavy PC infiltration; FISH: t(4;14) in 100%; del (17p) in 87%; gain of 1q21 in 80%; consistent with clonal evolution; Treatment: TOURMALINE-MM1 trial: ixazomib-rd/placebo-rd; 26 cycles; nadir 9 g/l; symptomatic progression after 26 cycles Learnings Rationale for continuous, especially in high-risk myeloma; role of FISH in newly diagnosed and relapsed myeloma ASCT, autologous stem cell transplant; BMA, bone marrow aspirate; CTD, cyclophosphamide-thalidomide-dexamethasone; DOR, duration of response; FISH, fluorescence in situ hybridisation; Hb, haemoglobin; Ig, immunoglobulin; IRd, ixazomib-lenalidomide-dexamethasone; ISS, International Staging System; PAD, bortezomib-doxorubicin-dexamethasone; PC, plasma cell; PR, partial response; Rd, lenalidomide-dexamethasone; VGPR, very good partial response.
16 Case study 2 (Dr Matthew Jenner) Thrombocytopenia Platelets x 10 9/ litre
17 Ixazomib-Rd was generally well tolerated with manageable side effects AEs after median follow-up of 23 months Moreau P et al. N Engl J Med 2016;374: Ixazomib-Rd (n=361), % Placebo-Rd (n=359), % Preferred terms All grades Grade 3 Grade 4 All grades Grade 3 Grade 4 AEs overlapping with lenalidomide Diarrhoea Constipation 35 < <1 0 Nausea Fatigue Vomiting <1 0 Rash* Back pain 24 < Upper respiratory tract infection 23 < <1 0 Thrombocytopenia AEs with proteasome inhibitors Peripheral neuropathies* Peripheral oedema AEs with lenalidomide Thromboembolism* 8 2 < <1 Neutropenia* *Represents multiple MedDRA preferred terms. AE, adverse event; Rd, lenalidomide-dexamethasone.
18 Special warnings and precautions for use: myelosuppression 1,2 For overlapping toxicities (thrombocytopenia, neutropenia and rash), the first dose reduction step is to reduce lenalidomide Platelet counts should be monitored at least monthly during ixazomib. More frequent monitoring should be considered during the first three cycles as per the lenalidomide SmPC An alternating dose modification approach is recommended for ixazomib and lenalidomide for overlapping toxicities of thrombocytopenia and neutropenia Withhold ixazomib and lenalidomide for platelet or neutrophil counts <30,000/mm 3 or <500/mm 3, respectively. Following recovery, resume lenalidomide at the next lower dose according to its SmPC and resume ixazomib at its most recent dose If platelet or neutrophil counts drop again to <30,000/mm 3 or <500/mm 3, withhold ixazomib and lenalidomide until recovery and resume ixazomib at the next lower dose and lenalidomide at its most recent dose 1. NINLARO (ixazomib capsules) Summary of Product Characteristics March 2017; 2.REVLIMID (lenalidomide) Summary of Product Characteristics March SmPC, summary of product characteristics.
19 Special warnings and precautions for use: gastrointestinal toxicities 1-3 Gastrointestinal (GI) toxicities have been observed to occur both with ixazomib and with the use of lenalidomide-dexamethasone, occasionally requiring use of antiemetics, antidiarrhoeals and supportive care The medical management of diarrhoea included the use of antidiarrhoeal agents and dose adjustment of lenalidomide or ixazomib For grade 3 or 4 GI toxicities, withhold the ixazomib dose. At the physician s discretion, generally recover to patient s baseline condition or at most grade 1 prior to resuming ixazomib. If attributable to ixazomib, resume ixazomib at the next lower dose following recovery. For lenalidomide-related toxicity, refer to its SmPC for dose adjustments In case of severe GI events, monitoring of serum potassium level is recommended 1. NINLARO (ixazomib capsules) Summary of Product Characteristics March 2017; 2. Moreau P et al. N Engl J Med 2016;374: ; 3. REVLIMID (lenalidomide) Summary of Product Characteristics March GI, gastrointestinal; SmPC, summary of product characteristics.
20 Special warnings and precautions for use: rash 1,2 For overlapping toxicities (thrombocytopenia, neutropenia and rash), the first dose reduction step is to reduce lenalidomide The medical management of rash included the use of antihistamines or topical glucocorticoids and dose adjustment to manage symptoms An alternating dose modification approach is recommended for ixazomib and lenalidomide for the overlapping toxicity of rash For grade 2 or 3 rash, withhold lenalidomide until rash recovers to grade 1 and resume lenalidomide at the next lower dose according to its SmPC If grade 2 or 3 rash occurs again, withhold ixazomib and lenalidomide until rash recovers to grade 1 then resume ixazomib at the next lower dose and lenalidomide at its most recent dose. For additional occurrences, alternate the dose modification of lenalidomide and ixazomib 1. NINLARO (ixazomib capsules) Summary of Product Characteristics March 2017; 2. Moreau P et al. N Engl J Med 2016;374: SmPC, summary of product characteristics.
21 Available for download at Patient support materials
22 A late response to therapy is not detrimental to overall outcomes Outcomes for patients in the TOURMALINE-MM1 study who achieved an early (0 4 month) or late (>4 month) response to therapy* ( PR) were compared. Outcomes Median number cycles Ixazomib-Rd Early (0 4 mos) n=174 Late (>4 mos) n=109 Early (0 4 mos) n=159 Placebo-Rd Late (>4 mos) n= Median PFS, mos 18.5 NE 14.9 NE Median DOR in PR pts, mos n=173 n=108 n=156 n= NE Premature discontinuation of therapy due to slow response should be avoided and patients should stay on therapy until progressive disease. Reprinted with permission from Laurent Garderet. Garderet L et al. Blood 2016;128(22): Abstract *Response was assessed every cycle based on central laboratory results and by IRC evaluation using IMWG criteria; Analysed to address the possibility of guarantee-time bias. DOR, duration of response; mos, months; IMWG, International Myeloma Working Group; IRC, independent review committee; NE, not estimable; PFS, progression-free survival; PR, partial response; Rd, lenalidomide-dexamethasone.
23 Case study 3 (Dr Karthik Ramasamy) Age 68 years Diagnosis June 2013 Presentation Anaemia leading to fatigue and hypercalcemia, Raised paraprotein levels. Right nephrectomy for previous renal cell carcinoma.
24 Case study 3 (Dr Karthik Ramasamy) Age 68 years Diagnosis June 2013 Presentation Anaemia leading to fatigue and hypercalcemia, Raised paraprotein levels. Right nephrectomy for previous renal cell carcinoma. Initial CTD x 5 followed by ASCT Decision point Decision made to treat because of symptoms and laboratory findings ASCT, autologous stem cell transplant; CTD, cyclophosphamide-thalidomide-dexamethasone.
25 Case study 3 (Dr Karthik Ramasamy) Age 68 years Diagnosis June 2013 Presentation Anaemia leading to fatigue and hypercalcemia, Raised paraprotein levels. Right nephrectomy for previous renal cell carcinoma. Initial CTD x 5 followed by ASCT Decision point Decision made to treat because of symptoms and laboratory findings Second Decision point VCD x 6 Developed hemianopia during cycle one due to posterior circulation stroke put down to history of diabetes mellitus. Grade 2 neuropathy. Did not progress on VCD Hypercalcaemia, rising paraprotein ASCT, autologous stem cell transplant; CTD, cyclophosphamide-thalidomide-dexamethasone; VCD, bortezomib-cyclophosphamide-dexamethasone.
26 Case study 3 (Dr Karthik Ramasamy) Age 68 years Diagnosis June 2013 Presentation Anaemia leading to fatigue and hypercalcemia, Raised paraprotein levels. Right nephrectomy for previous renal cell carcinoma. Initial CTD x 5 followed by ASCT Decision point Decision made to treat because of symptoms and laboratory findings Second Decision point Third VCD x 6 Developed hemianopia during cycle one due to posterior circulation stroke put down to history of diabetes mellitus. Grade 2 neuropathy. Did not progress on VCD Hypercalcaemia, rising paraprotein Ixazomib-Rd (time on ixazomib-rd: 7 8 months with best paraprotein response to date) ASCT, autologous stem cell transplant; CTD, cyclophosphamide-thalidomide-dexamethasone; Rd, lenalidomide-dexamethasone; VCD, bortezomib-cyclophosphamide-dexamethasone.
27 Case study 3 (Dr Karthik Ramasamy) Age 68 years Diagnosis June 2013 Presentation Anaemia leading to fatigue and hypercalcemia, Raised paraprotein levels. Right nephrectomy for previous renal cell carcinoma. Initial CTD x 5 followed by ASCT Decision point Decision made to treat because of symptoms and laboratory findings Second Decision point Third VCD x 6 Developed hemianopia during cycle one due to posterior circulation stroke put down to history of diabetes mellitus. Grade 2 neuropathy. Did not progress on VCD Hypercalcaemia, rising paraprotein Ixazomib-Rd (time on ixazomib-rd: 7 8 months with best paraprotein response to date) Learnings Good partial response with third-line ASCT, autologous stem cell transplant; CTD, cyclophosphamide-thalidomide-dexamethasone; Rd, lenalidomide-dexamethasone; VCD, bortezomib-cyclophosphamide-dexamethasone.
28 No difference in response by prior PI exposure 1,2 In TOURMALINE-MM1, 70% of patients had prior PI exposure (69% to bortezomib; 1% to carfilzomib) No difference was seen in response stratified by prior PI exposure Median PFS (months) Variable Subgroup Ixazomib-Rd Placebo-Rd HR All patients ALL Proteasome inhibitor Exposed Naive 18.4 NE Favours ixazomib-rd Favours placebo-rd Figure adapted from NINLARO Summary of Product Characteristics 1. Moreau P et al. N Engl J Med 2016;374: ; 2. NINLARO (ixazomib capsules) Summary of Product Characteristics March HR, hazard ratio; NE, not estimable; PI, proteasome inhibitor; PFS, progression-free survival; Rd, lenalidomide-dexamethasone.
29 Ixazomib exposure in renal impairment Phase 1/1b study Note that this Phase 1/1b study was not part of the registrational trial The Authors. British Journal of Haematology published by John Wiley & Sons Ltd. Gupta N et al. Br J Haematol 2016;174: ESRD, end-stage renal disease; MM, multiple myeloma; PK, pharmacokinetics; RI, renal impairment.
30 Ixazomib exposure in renal impairment Phase 1/1b study Similar absorption Higher unbound AUC in patients with severe RI/ESRD, standard dosing for ESRD patients: 3 mg Not dialysable 2016 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd. Gupta N et al. Br J Haematol 2016;174: AUC, area under the curve; ESRD, end-stage renal disease; RI, renal impairment.
31 Special populations: renal impairment No dose adjustment of ixazomib is required for patients with mild or moderate renal impairment (creatinine clearance 30 ml/min) The reduced dose of 3 mg is recommended in patients with severe renal impairment (creatinine clearance <30 ml/min) or end-stage renal disease requiring dialysis Ixazomib is not dialysable and, therefore, can be administered without regard to the timing of dialysis Refer to the lenalidomide SmPC for dosing recommendations in patients with renal impairment NINLARO (ixazomib capsules) Summary of Product Characteristics March SmPC, summary of product characteristics.
32 Quality of life maintained with ixazomib-rd vs. placebo-rd: EORTC-QLQ-C30 Quality of life was maintained with the addition of ixazomib to a standard Rd regimen Reprinted with permission from Philippe Moreau. Moreau P et al. Oral presentation 727, presented at ASH 2015 CI, confidence interval; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 module; EOT, end of ; QoL, quality of life; Rd, lenalidomide-dexamethasone.
33 Ixazomib-Rd regimen Ixazomib NINLARO (ixazomib capsules) Summary of Product Characteristics March *The recommended starting dose of dexamethasone is 40 mg; each tablet contain 2 mg dexamethasone.
34 Comparison in the number of planned hospital visits associated with adding PIs to the Rd backbone Route of administration Lenalidomide Dexamethasone PI Minimum number of clinic visits (18 cycles)* Rd 1 Ixazomib-Rd 2 Carfilzomib-Rd 3 PO PO Dosing schedule of PI PO PO PO PO PO/IV IV Once weekly on days 1, 8, and 15 of 28-day cycles Twice weekly on days 1, 2, 8, 9, 15, and 16 of 28-day cycles for 12 cycles then days 1, 2, 15, and REVLIMID (lenalidomide) Summary of Product Characteristics March 2017; 2. NINLARO (ixazomib capsules) Summary of Product Characteristics accessed March 2017; 3. KYPROLIS (carfilzomib) Summary of Product Characteristics March *Patients are treated until progression or unacceptable toxicity. Calculation excludes visits for monitoring. Standard carfilzomib regimen is 18 cycles; number of administrations of carfilzomib per cycle: cycle 1 12 = 6 doses (2 consecutive doses each week for 3 weeks), cycle = 4 doses (2 consecutive doses during 1st and 3rd week). Treatment with carfilzomib-rd for longer than 18 cycles should be based on an individual benefit-risk assessment, as the data on the tolerability and toxicity of carfilzomib beyond 18 cycles are limited. HRQoL, health-related quality of life; IV, intravenous; PI, proteasome inhibitor; PO, per os (oral); Rd, lenalidomide-dexamethasone.
35 Abbreviated prescribing information: NINLARO (ixazomib) Abbreviated Prescribing Information: NINLARO (ixazomib) (Refer to Summary of Product Characteristics (SmPC) before prescribing) Presentation: Ixazomib 2.3 mg, 3 mg and 4 mg hard capsules. Indication: NINLARO in combination with lenalidomide and dexamethasone is indicated for the of adult patients with multiple myeloma who have received at least one prior therapy. Dosage & Administration: Treatment must be initiated and monitored under the supervision of a physician experienced in the management of multiple myeloma. NINLARO should be used in combination with lenalidomide and dexamethasone. For additional information regarding lenalidomide and dexamethasone, refer to their SmPCs. The recommended starting dose of NINLARO is 4 mg (one capsule) administered orally once a week on Days 1, 8, and 15 of a 28-day cycle at least 1 hour before or at least 2 hours after food. The recommended starting dose of lenalidomide is 25 mg administered daily on Days 1 to 21 of a 28-day cycle. The recommended starting dose of dexamethasone is 40 mg administered on Days 1, 8, 15, and 22 of a 28-day cycle. Prior to initiating a new cycle of therapy, absolute neutrophil count should be 1,000/mm 3, platelet count should be 75,000/mm 3, non-haematologic toxicities should, at the physician s discretion, generally be recovered to patient s baseline condition or Grade 1. Treatment should be continued until disease progression or unacceptable toxicity. Treatment with NINLARO in combination with lenalidomide and dexamethasone for longer than 24 cycles should be based on an individual benefit risk assessment, as the data on the tolerability and toxicity beyond 24 cycles are limited. Antiviral prophylaxis should be considered in patients being treated with NINLARO to decrease the risk of herpes zoster reactivation. Thromboprophylaxis is recommended in patients being treated with NINLARO in combination with lenalidomide and dexamethasone, and should be based on an assessment of the patient s underlying risks and clinical status. Elderly: No dose adjustment is necessary in patients over 65 years of age. Renal impairment: Mild or moderate renal impairment, no dose adjustment is necessary. Reduced 3 mg starting dose recommended in severe renal impairment or end-stage renal disease requiring dialysis. Hepatic impairment: Mild hepatic impairment, no dose adjustment is necessary. Reduced 3 mg starting dose recommended in moderate or severe hepatic impairment. Paediatric population: No data are available. Contraindications: Hypersensitivity to the active substance or to its excipients. Warnings & Precautions: Thrombocytopenia: Thrombocytopenia has been reported with NINLARO with platelet nadirs typically occurring between Days of each 28-day cycle and recovery to baseline by the start of the next cycle. Thrombocytopenia did not result in an increase in haemorrhagic events or platelet transfusions. Platelet counts should be monitored at least monthly during NINLARO. Thrombocytopenia can be managed with dose modifications and platelet transfusions as per standard medical guidelines. Gastrointestinal toxicities: Diarrhoea, constipation, nausea and vomiting have been reported with NINLARO, occasionally requiring use of antiemetic and antidiarrhoeal medicinal products and supportive care. The dose should be adjusted for severe (Grade 3 4) symptoms. Peripheral neuropathy: Peripheral neuropathy has been reported with NINLARO. Patients should be monitored for symptoms of peripheral neuropathy. Patients experiencing new or worsening peripheral neuropathy may require dose modification. Peripheral oedema: Peripheral oedema has been reported with NINLARO. Patients should be evaluated for underlying causes and provide supportive care, as necessary. The dose of dexamethasone should be adjusted per its SmPC or NINLARO for Grade 3 or 4 symptoms. Cutaneous reactions: Rash has been reported with NINLARO. Rash should be managed with supportive care or with dose modification if Grade 2 or higher. Hepatotoxicity: Drug-induced liver injury, hepatocellular injury, hepatic steatosis, hepatitis cholestatic and hepatotoxicity have been uncommonly reported with NINLARO. Hepatic enzymes should be monitored regularly and the dose should be adjusted for Grade 3 or 4 symptoms. Pregnancy: Women should avoid becoming pregnant while being treated with NINLARO. Posterior reversible encephalopathy syndrome (PRES): PRES has occurred in patients receiving NINLARO. In patients developing PRES, discontinue NINLARO. Interactions: Strong cytochrome P450 (CYP) 3A inducers: Coadministration of strong CYP3A inducers with NINLARO is not recommended. Strong CYP3A inhibitors: No dose modification is required for NINLARO with co-administration of strong CYP3A inhibitors. Strong CYP1A2 inhibitors: No dose modification is required for NINLARO with co-administration of strong CYP1A2 inhibitors. Fertility, Pregnancy & Lactation: Women should avoid becoming pregnant while being treated with NINLARO. Male and female patients of childbearing potential must use effective contraceptive measures during and for 90 days following. Women using oral hormonal contraceptives should additionally use a barrier method of contraception. No data from use in pregnant women. Avoid use during pregnancy. Unknown whether NINLARO/metabolites are excreted in human milk, a risk to newborns/infants cannot be excluded; therefore breast feeding should be discontinued. The effect of NINLARO on fertility in humans has not been studied. Undesirable Effects: (All grades) Very common ( 1/10): Upper respiratory tract infection, thrombocytopenia, neutropenia, peripheral neuropathies, diarrhoea, nausea, vomiting, constipation, rash, back pain and oedema peripheral. Common ( 1/100, <1/10): Herpes zoster. Outside of the Phase 3 study, the following serious adverse reactions were rarely ( 1/10,000 to < 1/1,000) reported: acute febrile neutrophilic dermatosis, Stevens-Johnson syndrome, transverse myelitis, posterior reversible encephalopathy syndrome, tumour lysis syndrome and thrombotic thrombocytopenic purpura. Refer to the SmPC for details on full side effect profile and interactions. Pharmaceutical Precautions: Do not store above 30 C. Do not freeze. Store in the original package in order to protect from moisture. PI Date of Preparation: Dec 2016 PI approval code: UK/IXA/1611/0096 Legal category: POM Basic NHS Price: 6336 for 3 capsules. Marketing Authorisation: EU/1/16/1094/001, EU/1/16/1094/002, EU/1/16/1094/003 Further information is available from: Takeda UK Ltd. Building 3, Glory Park, Glory Park Avenue, Wooburn Green, Buckinghamshire, HP10 0DF. Tel: Fax: NINLARO is a registered trademark of Takeda Pharmaceutical Company Limited. NINLARO has received a conditional marketing authorisation in Europe. A conditional marketing authorisation is granted to a medicinal product that fulfils an unmet medical need when the benefit to public health of immediate availability outweighs the risk inherent in the fact additional data are still required. The European regulatory agency will review new information on NINLARO at least every year and the summary of product characteristics will be updated as necessary. Please refer to the Summary of Product Characteristics for details on the full side-effect profile and drug interactions of NINLARO. Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Takeda UK Ltd
The TOURMALINE-MM1 study: results and expert insights
The TOURMALINE-MM1 study: results and expert insights Professor Faith Davies UAMS Myeloma Institute, Arkansas, USA This educational meeting was organised and fully funded by Takeda UK Ltd. Takeda medicines
More informationIs sustained triplet therapy the new standard of care in relapsed/refractory multiple myeloma?
Takeda Oncology-sponsored satellite symposium at the British Society for Haematology (BSH) 57 th Annual Scientific Meeting Is sustained triplet therapy the new standard of care in relapsed/refractory multiple
More informationCurrent treatment options for relapsed/refractory multiple myeloma in practice
Current treatment options for relapsed/refractory multiple myeloma in practice Professor Marίa-Victoria Mateos University Hospital of Salamanca, Salamanca, Spain Please note that discussion throughout
More informationIxazomib with Lenalidomide and Dexamethasone (IRd)
Indication Ixazomib, with lenalidomide and dexamethasone, is recommended for use within the Cancer Drugs Fund as an option for treating multiple myeloma for patients who have already had 2 or 3 lines of
More informationWARNINGS AND PRECAUTIONS
DOSING GUIDE INDICATION NINLARO (ixazomib) is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
More informationNinlaro. (ixazomib) New Product Slideshow
Ninlaro (ixazomib) New Product Slideshow Introduction Brand name: Ninlaro Generic name: Ixazomib Pharmacological class: Proteasome inhibitor Strength and Formulation: 2.3mg, 3mg, 4mg; gel caps Manufacturer:
More informationCarfilzomib and Dexamethasone (CarDex)
Carfilzomib and Dexamethasone (CarDex) Indication Relapsed multiple myeloma for patients who have had only one previous line of therapy (that did not include bortezomib). (NICE TA457) ICD-10 codes Codes
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationNovel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors
Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors Antonio Palumbo M.D. Takeda Pharmaceuticals International AG Introduction Multiple genetically-distinct subclones
More informationBortezomib, Thalidomide and Dexamethasone (VTD) 28 day
Bortezomib, Thalidomide and Dexamethasone (VTD) 28 day Indication First line treatment of multiple myeloma in patients who are eligible for stem cell transplantation. (NICE TA311) ICD-10 codes Codes with
More informationFOR IMMEDIATE RELEASE
FOR IMMEDIATE RELEASE FOR UK MEDICAL AND TRADE MEDIA ONLY Takeda Presents Data from TOURMALINE-MM1 Study for Ixazomib, the First and Only Once-Weekly Oral Proteasome Inhibitor Studied in Phase III Clinical
More informationPractical Considerations in Multiple Myeloma: Optimizing Therapy With New Proteasome Inhibitors
Welcome to Managing Myeloma. My name is Dr. Donald Harvey. I am Director of Phase 1 Clinical Trials Section and an Associate Professor in Hematology, Medical Oncology, and Pharmacology at the Winship Cancer
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationPanobinostat, Bortezomib and Dexamethasone
Panobinostat, Bortezomib and Dexamethasone Indication Treatment of relapsed/refractory multiple myeloma in patients who have received at least 2 prior regimens, including bortezomib and an immunomodulatory
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationNCCP Chemotherapy Regimen. Carfilzomib, Lenalidomide and Dexamethasone (KRd) Therapy - 28 day
, Lenalidomide and Dexamethasone (KRd) Therapy - INDICATIONS FOR USE: INDICATION ICD10 Regimen Code Reimbursement Status *, lenalidomide and dexamethasone therapy is indicated for the treatment of adult
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION NINLARO
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr NINLARO ixazomib (as ixazomib citrate) 4 mg, 3 mg and 2.3 mg capsules Antineoplastic Agent Takeda Canada Inc. 2201 Bristol Circle, Suite 700
More informationRegimen Protocols IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone
Regimen Protocols IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone Constituents of Regimen: ixazomib, lenalidomide, dexamethasone Other Names of Regimen Constituents and Unique Ingredient Identifier
More informationProteasome inhibitor (PI) and immunomodulatory drug (IMiD) refractory multiple myeloma is associated with inferior patient outcomes
Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor
More informationMethods: Studies included in the analysis
Efficacy and safety of long-term ixazomib maintenance therapy in patients with newly diagnosed multiple myeloma not undergoing transplant: An integrated analysis of four phase 1/2 studies Meletios A. Dimopoulos,
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationSUBCUTANEOUS Bortezomib + Thalidomide +Dexamethasone Available for Routine Use in
SUBCUTANEOUS Bortezomib + Thalidomide +Dexamethasone Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby
More informationMarc Geirnaert Director of Provincial Oncology Drug Program CancerCare Manitoba
Marc Geirnaert Director of Provincial Oncology Drug Program CancerCare Manitoba Advisory board participant for lenalidomide in 2013 Not applicable Understand the role of prophylaxis for herpes zoster Be
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationModel-Informed Drug Development (MIDD) for Ixazomib, an Oral Proteasome Inhibitor
Model-Informed Drug Development (MIDD) for Ixazomib, an Oral Proteasome Inhibitor Neeraj Gupta, Michael J. Hanley, Paul M. Diderichsen, 2 Huyuan Yang, Yeamin Huh, Alice Ke, 4 Zhaoyang Teng, Richard Labotka,
More informationPOMALYST (pomalidomide) for Previously Treated Multiple Myeloma
POMALYST (pomalidomide) for Previously Treated What is POMALYST? POMALYST (pomalidomide) capsule is an oral immunomodulatory therapy (a thalidomide analogue) indicated for patients with multiple myeloma
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy
More informationThe drug cost of lenalidomide for people who remain on treatment for more than 26 cycles will be met by the company.
LENALIDOMIDE MDS NICE TA322 Treatment of patients with transfusion-dependent anaemia (< 8 consecutive weeks without RBC transfusions within 16 weeks prior to commencing treatment) due to low- or intermediate-1-risk
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationNovel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma
Novel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma Ravi Vij, MD MBA Professor of Medicine Washington University School of Medicine Section of Stem Cell Transplant
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationMyeloma and renal failure Future directions. Karthik Ramasamy
Myeloma and renal failure Future directions Karthik Ramasamy Overview Historical perspective & Background Drug interventions & trials OPTIMAL Trial Future directions Burden of disease Upto 40% of newly
More informationDOSING FLEXIBILITY OF REVLIMID
REVLIMID Dose Adjustments for Renal Impairment DISCOVER THE DOSING FLEXIBILITY OF REVLIMID FOR PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) REVLIMID (lenalidomide) is indicated for the treatment of patients
More informationNovel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
More informationRefractory M ultiple Multiple M yeloma Myeloma
Refractory Multiple Myeloma A Case Study Case: #1 48-Year-Old Male Presented to the ER with Fatigue and Acute Severe Lower Back Pain Patient assessment: X-ray of lumbar spine: L4 compression fracture,
More informationTreatment Strategies for Transplant-ineligible NDMM Patients
1 Treatment Strategies for Transplant-ineligible NDMM Patients Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Multiple Myeloma affects primarily
More informationCost-effectiveness of ixazomib (Ninlaro ) for the Treatment of Adult Patients with Multiple Myeloma who have Received at Least One Prior Therapy
Cost-effectiveness of ixazomib (Ninlaro ) for the Treatment of Adult Patients with Multiple Myeloma who have Received at Least One Prior Therapy The NCPE has issued a recommendation regarding the cost-effectiveness
More informationSummary of the risk management plan (RMP) for Kyprolis (carfilzomib)
EMA/639793/2015 Summary of the risk management plan (RMP) for Kyprolis (carfilzomib) This is a summary of the risk management plan (RMP) for Kyprolis, which details the measures to be taken in order to
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationWARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,
Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901 Tel 908-673-9000 Fax 908-673-9001 October 2012 NEW Indication Announcement for ABRAXANE for Injectable Suspension (paclitaxel protein-bound
More informationCARFILZOMIB /DEXAMETHASONE (CarDex)
CARFILZOMIB /DEXAMETHASONE (CarDex) INDICATIONS First Relapse multiple myeloma in bortezomib naïve patients [NICE TA457] Requires Blueteq Application TREATMENT INTENT Disease modification PRE-ASSESSMENT
More informationDOSING FLEXIBILITY OF REVLIMID
REVLIMID Dose Adjustments for Thrombocytopenia DISCOVER THE DOSING FLEXIBILITY OF REVLIMID FOR PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) REVLIMID (lenalidomide) is indicated for the treatment of patients
More informationManagement of Multiple Myeloma
Management of Multiple Myeloma Damian J. Green, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance New Treatment Options Have Improved OS in MM Kumar SK, et al. Blood. 2008;111:2516-2520.
More informationManaging Major Adverse Events in Relapsed/Refractory Multiple Myeloma
Welcome to Managing Myeloma. I am Dr. Ajay Nooka. In today's presentation, I will discuss managing major adverse events in relapsed/refractory multiple myeloma. In this video, I will provide you with information
More informationTREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE
TREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE PRESENTED BY: Pooja Chaukiyal MD Hematologist/Oncologist New York Oncology Hematology Albany, NY April 16, 2016 Background The prognosis for patients
More informationSkin Pathway Group Alemtuzumab in Cutaneous Lymphoma
Skin Pathway Group Alemtuzumab in Cutaneous Lymphoma Indication: Treatment of patients with Cutaneous Lymphoma (Unlicensed use) Disease control prior to Reduced Intensity Conditioning Stem Cell Transplant
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients With to 3 Prior Lines of Therapy Based on
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationDaratumumab: Mechanism of Action
An Open-label, Randomised, Phase 3 Study of Daratumumab, Lenalidomide, and Dexamethasone (D) Versus Lenalidomide and Dexamethasone () in Relapsed or Refractory Multiple Myeloma (RRMM): POLLUX* Meletios
More informationPomalidomide and Dexamethasone INDICATIONS FOR USE:
Pomalidomide and INDICATIONS FOR USE: INDICATION Treatment in combination with dexamethasone of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment
More informationAntibodies are a standard part of first relapse management in multiple myeloma (MM): Yes
Antibodies are a standard part of first relapse management in multiple myeloma (MM): Yes Ajay Nooka, MD MPH FACP Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory
More informationPomalidomide and Dexamethasone Therapy
INDICATIONS FOR USE: Pomalidomide and Therapy Regimen Code INDICATION ICD10 Treatment in combination with dexamethasone of adult patients with relapsed and refractory multiple myeloma who have received
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationBCCA Protocol Summary for Therapy of Relapsed Multiple Myeloma Using Lenalidomide with Dexamethasone
BCCA Protocol Summary for Therapy of Relapsed Multiple Myeloma Using Lenalidomide with Dexamethasone Protocol Code Tumour Group Contact Physician Contact Pharmacist UMYLDREL Lymphoma, Leukemia/BMT Dr.
More informationBCCA Protocol Summary for Therapy of Multiple Myeloma Using Pomalidomide with Dexamethasone
BCCA Protocol Summary for Therapy of Multiple Myeloma Using Pomalidomide with Dexamethasone Protocol Code UMYPOMDEX Tumour Group Contact Physician Contact Pharmacist Lymphoma, Leukemia/BMT Dr. Kevin Song
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationCARFILZOMIB/ LENALIDOMIDE / DEXAMETHASONE (Car/Len/Dex)
CARFILZOMIB/ LENALIDOMIDE / DEXAMETHASONE (Car/Len/Dex) INDICATIONS Relapsed multiple myeloma This combination is not funded by NHS England. Individual funding must be agreed prior to initiation. TREATMENT
More informationTreatment of Relapsed. A Case Study
Treatment of Relapsed Multiple Myeloma A Case Study Case Presentation Mr. V is a 61-year-old man previously diagnosed with ISS stage III IgG λ multiple myeloma with bone lesions, normal FISH and cytogenetics,
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationMabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection
MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults
More informationBC Cancer Protocol Summary for Maintenance Therapy of Multiple Myeloma Using Lenalidomide
BC Cancer Protocol Summary for Maintenance Therapy of Multiple Myeloma Using Lenalidomide Protocol Code Tumour Group Contact Physician Contact Pharmacist UMYLENMTN Lymphoma, Leukemia/BMT Dr. Kevin Song
More informationPhase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Phase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Jatin J Shah, MD, Sheeba Thomas, MD, Donna Weber, MD, Michael Wang, MD, Raymond Alexanian, MD, Robert
More informationDARZALEX. daratumumab PRODUCT INFORMATION. DARZALEX (daratumumab) 20 mg/ml concentrate for solution for infusion. CAS Registry Number:
NAME OF THE MEDICINE DARZALEX daratumumab PRODUCT INFORMATION DARZALEX (daratumumab) 20 mg/ml concentrate for solution for infusion. CAS Registry Number: 945721-28-8. DESCRIPTION Daratumumab is an immunoglobulin
More informationTechnology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta380
Panobinostat for treating multiple myeloma after at least 2 previous treatments Technology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta380 NICE 2017. All rights reserved. Subject
More information* Dose may vary dependent on tolerability and co-morbidities
BC Cancer Protocol Summary for Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant Using Lenalidomide with Low-dose Dexamethasone Protocol Code Tumour Group Contact
More informationBortezomib and Dexamethasone Therapy INDICATIONS FOR USE:
Bortezomib and Dexamethasone Therapy INDICATIONS FOR USE: INDICATION Treatment of adult patients with progressive multiple myeloma who have received at least one prior therapy ICD10 C90 Protocol Code 00270a
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationASCO Analyst & Investor Webcast. June 1, 2018
ASCO Analyst & Investor Webcast June 1, 2018 June 1, 2018 NASDAQ: BLUE Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information
More informationqthis medicinal product is subject to additional monitoring. This will allow quick identification of new safety
Parsabiv q (etelcalcetide) Frequently Asked Questions qthis medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals
More informationLONDON CANCER NEWS DRUGS GROUP RAPID REVIEW
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Bortezomib as first line induction prior to melphalan and autologous stem cell transplantation (ASCT) in untreated symptomatic multiple myeloma patients suitable
More informationPOMALIDOMIDE AND LOW DOSE DEXAMETHASONE
POMALIDOMIDE AND LOW DOSE DEXAMETHASONE INDICATION Multiple myeloma at third or subsequent relapse, i.e. after 3 previous treatments including both lenalidomide and bortezomib. (NICE TA427 -BLUETEQ required)
More informationAHFS Final. Criteria Used in. Strength. Grade of. hydrochloride. per day on 12, and mg/m 2 IV. Strength. Grade of. Bortezomib 1.
AHFS Final Determination of Medical Acceptance: Off-label Use of Bortezomib in Combination with Doxorubicin and Dexamethasone as Inductionn Therapy for Newly Diagnosed Multiple Myeloma in Transplant-eligible
More informationIMiDs (Immunomodulatory drugs) and Multiple Myeloma
www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com
More informationDERBY-BURTON LOCAL CANCER NETWORK FILENAME Lenalidomide_MDS.DOC CONTROLLED DOC NO: HCCPG B78 CSIS Regimen Name: LEN_MDS.
Lenalidomide Available for Routine Use in Burton in-patient N/A Derby in-patient Burton day-case Derby day-case Burton outreach chemotherapy clinic N/A Derby outreach chemotherapy clinic Burton out-patient
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationCyBorD/ Cylophosphamide, Bortezomib, and
CyBorD/ Cylophosphamide, Bortezomib, and Dexamethasone-21 day Therapy i INDICATIONS FOR USE: INDICATION ICD10 Protocol Code Treatment of newly diagnosed symptomatic multiple myeloma i C90 00273a Treatment
More informationDARZALEX. daratumumab NEW ZEALAND DATA SHEET
1 PRODUCT NAME DARZALEX daratumumab NEW ZEALAND DATA SHEET DARZALEX (daratumumab) 20 mg/ml concentrate for solution for infusion. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5 ml vial contains 100
More informationScottish Medicines Consortium
Scottish Medicines Consortium lenalidomide, 5mg,10mg,15mg and 25mg capsules (Revlimid) No. (441/08) Celgene Europe Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment of
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationBackground Information
What is Velcade (bortezomib)? Velcade (bortezomib) is a medicine used to treat a blood cancer known as multiple myeloma, and was the first of the treatments in the class of anti-cancer drugs known as proteasome
More informationManaging Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient. Case Study
Managing Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient Case Study 2 2011 Newly Diagnosed Patient The patient is a 61-year-old Caucasian female History of high blood pressure
More informationMantle cell lymphoma An update on management
Mantle cell lymphoma An update on management Dr Kim Linton Consultant Medical Oncologist The Christie NHS Foundation Trust 6 th October 2016 This educational meeting is organised and sponsored by Janssen-Cilag
More informationShould we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain
Should we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain Should we treat some patients with Stage I MM? Len-dex is a promising and atractive option
More informationCyclophosphamide, Thalidomide and Dexamethasone- attenuated (CTDa) MMWOS003/01 Indication Oral treatment for multiple myeloma
West of Scotland Cancer Network Chemotherapy Protocol, and - attenuated (CTDa) MMWOS003/01 Indication Oral treatment for multiple myeloma Eligibility criteria Confirmed diagnosis of multiple myeloma First
More informationNCCP Chemotherapy Regimen. Ibrutinib Therapy Mantle Cell Lymphoma
INDICATIONS FOR USE: Ibrutinib Therapy Mantle Cell Lymphoma INDICATION ICD10 Regimen Code *Reimbursement Indicator As a single agent for the treatment of adult patients with relapsed or refractory mantle
More informationREVLIMID is only available through a restricted distribution program, REVLIMID REMS. Please see additional Important Safety Information on pages
REVLIMID is only available through a restricted distribution program, REVLIMID REMS. Please see additional Important Safety Information on pages 11-12 and accompanying full Prescribing Information, including
More informationMultiple Myeloma Brian Berryman, M.D. March 8 th, 2014
Multiple Myeloma 2014 Brian Berryman, M.D. March 8 th, 2014 Kyle, R. A. et al. Blood 2008;111:2962-2972 Updates in Multiple Myeloma CCO Independent Conference Coverage of the 2013 Annual Meeting of
More informationGazyva (obinutuzumab)
STRENGTH DOSAGE FORM ROUTE GPID 1000mg/40mL Vial Intravenous 35532 MANUFACTURER Genentech, Inc. INDICATION(S) Gazyva (obinutuzumab) is a CD20- directed cytolytic antibody and is indicated, in combination
More informationFuture Strategies For Refractory Myeloma. Marc S. Raab
Future Strategies For Refractory Myeloma Marc S. Raab Multiple Myeloma Clonal proliferation of malignant plasma cells. excess bone marrow plasma cells monoclonal protein osteolytic bone lesions renal disease
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm Frontline Therapy for Newly Diagnosed Patients Saad Usmani, MD FACP Levine Cancer Institute Introduction: Case Presentation 64-year-old woman with
More information